近期诊断非肌层浸润性膀胱癌患者自报吸烟相关暴露的准确性
该横断面分析纳入517例近期诊断的非肌层浸润性膀胱癌患者,同日采集尿液或唾液标本并自我报告吸烟、电子烟、尼古丁替代治疗及与吸烟者同住情况,以可替宁作为近期尼古丁暴露的客观生物标志物。结果显示自报当前吸烟的敏感性仅58%,考虑其他尼古丁来源后升至82%,提示需生物化学验证或补充询问其他来源以准确识别吸烟相关暴露。
要点
- 自报当前吸烟的敏感性仅58%,考虑其他尼古丁来源后升至82%。
- 33%患者可替宁提示无暴露,54%低暴露,13%高暴露。
- 低可替宁患者几乎均否认任何吸烟相关暴露。
核心结论
- 仅靠自报当前吸烟会低估非肌层浸润性膀胱癌患者的吸烟相关暴露,需可替宁验证或补充询问其他尼古丁来源。
研究设计与样本
- 横断面分析纳入517例近期诊断的非肌层浸润性膀胱癌患者,同日采集尿液或唾液标本并自我报告吸烟相关暴露。
主要发现
- 高、低、无可替宁暴露的患病率分别为13%、54%、33%。
- 7.3%(38/517)患者自报当前吸烟,13%(65/517)可替宁水平符合主动吸烟暴露。
- 65例可替宁提示主动吸烟者中27例否认当前吸烟,自报当前吸烟敏感性为58%。
- 考虑电子烟、雪茄、尼古丁替代治疗及与吸烟者同住等其他来源后,敏感性升至82%。
- 低可替宁患者几乎均否认任何吸烟相关暴露。
临床怎么用
- 临床应使用可替宁生物化学验证或补充询问其他尼古丁来源,以准确识别吸烟相关暴露并指导戒烟建议。
- 准确分类主动与被动吸烟暴露有助于研究者估计诊断后吸烟相关暴露与非肌层浸润性膀胱癌复发风险的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cigarette smoking is a risk factor for developing nonmuscle invasive bladder cancer, and continued smoking exposure after diagnosis may increase the likelihood of adverse clinical outcomes. We compare self-reported vs biochemically verified nicotine exposure to determine the accuracy of self-report among recently diagnosed nonmuscle invasive bladder cancer patients. MATERIALS AND METHODS: This cross-sectional analysis consisted of 517 nonmuscle invasive bladder cancer patients who contributed a urine or saliva specimen the same day as self-reporting their smoking, use of e-cigarettes, nicotine replacement therapy and whether they lived with a smoker. Cotinine, the primary metabolite of nicotine, was used as an objective biomarker of recent nicotine exposure. RESULTS: The prevalence of high, low and no cotinine exposure was 13%, 54% and 33%, respectively. Overall, 7.3% of patients (38/517) reported being a current cigarette smoker, while 13% (65/517) had cotinine levels consistent with active smoking exposure. Of these 65 patients 27 denied current smoking, resulting in a sensitivity of self-reported current smoking of 58%. After considering other sources of nicotine exposure such as e-cigarettes, cigars, nicotine replacement therapy and living with a smoker, the sensitivity was higher, at 82%. Nearly all patients with low cotinine denied any smoking-related exposure. CONCLUSIONS: Our findings suggest either biochemical verification with cotinine or additional questions about other sources of nicotine are needed to accurately identify nonmuscle invasive bladder cancer patients who have smoking-related exposures. Accurate classification of active and passive smoking exposure is essential to allow clinicians to advise cessation and help researchers estimate the association between post-diagnosis smoking-related exposure and nonmuscle invasive bladder cancer recurrence risk.
引用
- Petruzella S, Bochner BH, Kenney J, et al. Examining the Accuracy of Self-Reported Smoking-Related Exposure among Recently Diagnosed Nonmuscle Invasive Bladder Cancer Patients. J Urol. 2020. PMID: 33356484. doi:10.1097/JU.0000000000001571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。